SCHEMBL4284077

SCHEMBL4284077

CCc1ccc(Cl)cc1B(O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGPS1 O95749 1/20 0.41
LMNA P02545 2/20 0.40
MAPK1 P28482 2/20 0.40
NLRP1 Q9C000 1/20 0.40
ENPP2 Q13822 2/20 0.38
IDO1 P14902 2/20 0.38
CYP3A4 P08684 2/20 0.38
MEN1 O00255 1/20 0.38
SLC22A1 O15245 1/20 0.38
USP2 O75604 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPT P10636 1/20 0.38
HSPD1 P10809 1/20 0.38
HSPA5 P11021 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
CASP1 P29466 1/20 0.38
HTT P42858 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560893 0.85 ALOX5 (0.41) ENPP2FLT1FLT4KDRCYP1A2
SCHEMBL12556949 0.83 HIF1A (0.42) LMNAMAPK1NLRP1ENPP2IDO1
SCHEMBL16576628 0.82 GGPS1 (0.38) GGPS1LMNAMAPK1ENPP2IDO1
SCHEMBL3787954 0.77 LPL (0.50) LMNAMAPK1NLRP1MAPTSMN1; SMN2
SCHEMBL419197 0.75 TSHR (0.38) LMNAMAPK1MAPTHPGDSMN1; SMN2
SCHEMBL3782085 0.75 IDO1 (0.44) GGPS1LMNAMAPK1NLRP1IDO1
SCHEMBL23730533 0.74 LIPG (0.39) ENPP2ALOX15ALOX12POLBTDP1
SCHEMBL1005910 0.74 HSD17B10 (0.50) LMNAMAPK1NLRP1IDO1CYP3A4
SCHEMBL20245771 0.73 FLT1 (0.43) LMNAENPP2IDO1CYP3A4MEN1
SCHEMBL12101764 0.73 ALOX5 (0.41) ENPP2CTRCERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2736514-B1 ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-10-18 EP disclosed
EP-2736514-B1 ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-10-18 EP disclosed
EP-2699564-B1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-12-14 EP disclosed
EP-2699564-B1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-12-14 EP disclosed
US-9283224-B2 Substituted pyrimidinyl-pyrroles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-15 US disclosed
US-9284298-B2 Pyrazolyl-pyrimidine derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-15 US disclosed
US-9284298-B2 Pyrazolyl-pyrimidine derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-15 US disclosed
US-9283224-B2 Substituted pyrimidinyl-pyrroles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-15 US disclosed
US-8912200-B2 Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-12-16 US disclosed
US-8912200-B2 Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-12-16 US disclosed
US-20140051708-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-20 US disclosed
US-20140051708-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-20 US disclosed
US-20140051708-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-20 US disclosed
WO-2013014039-A1 ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-31 WO disclosed
WO-2012143248-A1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-26 WO disclosed
WO-2012139930-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-18 WO disclosed
WO-2012139930-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-18 WO disclosed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT GGPS1 74/4885LMNA 1834/4885MAPK1 3470/4885
US-20140051708-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS MAP3K1, MAP3K20, MAP3K6 GGPS1 1036/4885LMNA 2837/4885MAPK1 225/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT GGPS1 73/4885LMNA 1671/4885MAPK1 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.